Table 1 Baseline demographics and disease characteristics
| Â | Part A | Part B | ||||||
|---|---|---|---|---|---|---|---|---|
| Â | Â | AMG 108 | Â | Â | ||||
| Â | Placebo ( n = 16) | 100 mg IV ( n = 12) | 300 mg IV ( n = 12) | 300 mg SC ( n = 12) | 75 mg SC ( n = 12) | All AMG 108 ( n = 48) | Placebo ( n = 80) | AMG 108 300 mg SC ( n = 80) |
Mean age (years) | 60.8 | 61.1 | 62.8 | 59.6 | 62.3 | 61.4 | 60.1 | 61.3 |
Female, n (%) | 10 (63) | 11 (92) | 7 (58) | 5 (42) | 9 (75) | 32 (67) | 54 (68) | 54 (68) |
Ethnicity, n (%) | Â | Â | Â | Â | Â | Â | Â | Â |
   White | 15 (94) | 12 (100) | 12 (100) | 12 (100) | 12 (100) | 48 (100) | 66 (83) | 67 (84) |
   Black | 1 (6) | 0 | 0 | 0 | 0 | 0 | 2 (3) | 7 (9) |
   Hispanic | - | - | - | - | - | - | 12 (15) | 6 (8) |
Mean weight (kg) | 83.8 | 79.9 | 90.7 | 85.5 | 82.4 | 84.6 | 87.6 | 88.2 |
Mean BMI (kg/m2) | 30.4 | 30.8 | 31.9 | 29.8 | 30.9 | 30.8 | 31.9 | 32.0 |
Duration of OA (years) | 9.6 | 6.9 | 10.2 | 6.6 | 10.0 | 8.4 | 6.1 | 6.1 |
Kellgren-Lawrence score (n (%)) | Â | Â | Â | Â | Â | Â | Â | Â |
   1 | 2 (13) | 3 (25) | 1 (8) | 0 | 3 (25) | 7 (15) | 4 (5) | 1 (1) |
   2 | 4 (25) | 3 (25) | 7 (58) | 5 (42) | 4 (33) | 19 (40) | 30 (38) | 40 (50) |
   3 | 10 (63) | 6 (50) | 4 (33) | 7 (58) | 5 (42) | 22 (46) | 46 (58) | 39 (49) |